Elbrus-2S+ Elbrus-2S+ Elbrus-2S+ () is a multi-core microprocessor based on the Elbrus 2000 architecture developed by Moscow Center of SPARC Technologies (MCST) There are multiple reports regarding the evolution of this technology for the purpose of import substitution in Russia, which was raised by several ministries on July 2014, due to economic sanctions in response to 2014 pro-Russian unrest in Ukraine. In December 2014, it was announced that Mikron start pilot production of a dual-core variant of this microprocessor called Elbrus-2SM () using a 90 nanometer CMOS manufacturing process in Zelenograd, Russia. The Elbrus-4S CPU is reported to have built in
MT-45 States the DEA placed MT-45 in Schedule 1 of the Controlled Substance Act. This took effect January 12, 2018. MT-45 MT-45 (IC-6) is an opioid analgesic drug invented in the 1970s by Dainippon Pharmaceutical Co. It is chemically a 1-substituted-4-(1,2-diphenylethyl)piperazine derivative, which is structurally unrelated to most other opioid drugs. Racemic MT-45 has around 80% the potency of morphine, with almost all opioid activity residing in the (S) enantiomer (the opposite stereochemistry from the related drug lefetamine). It has been used as a lead compound from which a large family of potent opioid drugs have been developed, including full agonists,